The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis

被引：48
作者：
Zhao, Mingfei [1 ]
Liang, Feng [1 ]
Zhang, Buyi [2 ]
Yan, Wei [1 ]
Zhang, Jianmin [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurosurg, Hangzhou 310009, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Pathol, Hangzhou 310009, Zhejiang, Peoples R China
来源：
SCIENTIFIC REPORTS | 2015年 / 5卷
基金：
中国国家自然科学基金;
关键词：
EXPRESSION; MARKERS; TARGET; GENE;
D O I：
10.1038/srep12713
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Colorectal cancer (CRC) is one of the most frequent malignant neoplasms worldwide. Up to now, no biomarker has been used to predict the prognosis and surveillance of patients with CRC. Recently, the association between osteopontin (OPN) overexpression and the prognosis of CRC was investigated widely, but the results were inconsistent. Therefore, the aim of present meta-analysis was to assess the prognostic effect of osteopontin in patients with CRC. PubMed, EMBASE, Web of Science, Scopus and Chinese Medical Database were systematically searched. A total of 15 studies containing 1698 patients were included in our meta-analysis. The pooled data of studies showed that high OPN expression was significantly associated with high tumor grades (OR = 2.24, 95% CI 1.55-3.23), lymph node metastasis (OR = 2.36, 95% CI 1.71-3.26) and tumor distant metastasis (OR = 2.38, 95% CI 1.01-5.60). Moreover, high OPN expression was significantly associated with the 2-year (HR 1.97, 95% CI 1.30-3.00), 3-year (HR 1.82, 95% CI 1.24-2.68), 5 year (HR 1.53, 95% CI 1.28-1.82) survival rates and overall survival (OS, HR 1.70, 95% CI 1.12-2.60), respectively. These results indicated that OPN could serve as a prognostic biomarker and as a potential therapeutic target for CRC.
引用
收藏
页数：8
相关论文
共 28 条
[1]   Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity [J].
Ashkar, S ;
Weber, GF ;
Panoutsakopoulou, V ;
Sanchirico, ME ;
Jansson, M ;
Zawaideh, S ;
Rittling, SR ;
Denhardt, DT ;
Glimcher, MJ ;
Cantor, H .
SCIENCE, 2000, 287 (5454) :860-864
[2]   Osteopontin as a therapeutic target for cancer [J].
Bandopadhyay, Monalisa ;
Bulbule, Anuradha ;
Butti, Ramesh ;
Chakraborty, Goutam ;
Ghorpade, Priyanka ;
Ghosh, Pompom ;
Gorain, Mahadeo ;
Kale, Smita ;
Kumar, Dhiraj ;
Kumar, Santosh ;
Totakura, Kumar V. S. ;
Roy, Gaurab ;
Sharma, Priyanka ;
Shetti, Dattatrya ;
Soundararajan, Gowrishankar ;
Thorat, Dhanashri ;
Tomar, Deepti ;
Nalukurthi, Radha ;
Raja, Remya ;
Mishra, Rosalin ;
Yadav, Amit S. ;
Kundu, Gopal C. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (08) :883-895
[3]   Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial [J].
Bramwell, Vivien H. C. ;
Tuck, Alan B. ;
Chapman, Judith-Anne W. ;
Anborgh, Pieter H. ;
Postenka, Carl O. ;
Al-Katib, Waleed ;
Shepherd, Lois E. ;
Han, Lei ;
Wilson, Carolyn F. ;
Pritchard, Kathleen I. ;
Pollak, Michael N. ;
Chambers, Ann F. .
BREAST CANCER RESEARCH, 2014, 16 (01)
[4]   Compliance, attitudes and barriers to post-operative colorectal cancer follow-up [J].
Cardella, Jonathan ;
Coburn, Natalie G. ;
Gagliardi, Anna ;
Maier, Barbara-Anne ;
Greco, Elisa ;
Last, Linda ;
Smith, Andrew J. ;
Law, Calvin ;
Wright, Frances .
JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2008, 14 (03) :407-415
[5]  
Chen S. H., 2007, MODERN ONCOLOGY, V115, P1132
[6]  
Chen Y., 2009, CLIN MED J CHINA, V16, P94
[7]   Osteopontin, CD44, and NFκB Expression in Gastric Adenocarcinoma [J].
Kim, Jung Yeon ;
Bae, Byung-Noe ;
Kim, Kyoung Soo ;
Shin, Eunah ;
Park, Kyeongmee .
CANCER RESEARCH AND TREATMENT, 2009, 41 (01) :29-35
[8]   Prognostic Value of CEA and CA 19-9 Tumor Markers Combined with Cytology from Peritoneal Fluid in Colorectal Cancer [J].
Lee, In Kyu ;
Kim, Do Hyoung ;
Gorden, D. Lee ;
Lee, Yoon Suk ;
Sung, Na Young ;
Park, Gyeoung-Sin ;
Kim, Hyung Jin ;
Kang, Won Kyung ;
Park, Jong Kyung ;
Ahn, Chang Hyeok ;
Kim, Jun-Gi ;
Jeon, Hae Myung ;
Oh, Seong Taek .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (04) :861-870
[9]   Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry [J].
Li, Jing ;
Yang, Guang-Zhi ;
Zhu, Zi-Man ;
Zhou, Zhi-Yong ;
Li, Lin .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (04) :621-624
[10]   Comparative Profiling of Primary Colorectal Carcinomas and Liver Metastases Identifies LEF1 as a Prognostic Biomarker [J].
Lin, Albert Y. ;
Chua, Mei-Sze ;
Choi, Yoon-La ;
Yeh, William ;
Kim, Young H. ;
Azzi, Raymond ;
Adams, Gregg A. ;
Sainani, Kristin ;
van de Rijn, Matt ;
So, Samuel K. ;
Pollack, Jonathan R. .
PLOS ONE, 2011, 6 (02)
123